Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition
Siker Kimbung(Lund University), Ingrid Hedenfalk(Lund University), Ewa Biskup(Jagiellonian University), Kristina Aaltonen(Lund University), Ida Johansson(Lund University), Sofia K. Gruvberger-Saal(Lund University), Heather E. Cunliffe(Translational Genomics Research Institute), Niklas Loman(Lund University), Bengt Fadeel(Karolinska Institutet), Pontus Berglund(Lund University), Astrid Ottosson-Wadlund(Karolinska Institutet)
Cited by 44
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
|Cancer Cell|2017|534